In a previous study, the authors had treated six patients with advanced melanoma and showed, that despite including HLA class I-binding peptides (for CD8+ T-cell recognition) in the vaccine design, superior CD4+ T-cell responses directed against the patients’ neoantigens was observed (69). Here, CD8A is linked to melanoma.